SCHEMBL932893

SCHEMBL932893

OCc1ccc(Cl)c(C(F)(F)F)c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.61
S1PR1 P21453 1/20 0.55
PYCR1 P32322 1/20 0.50
GPR84 Q9NQS5 1/20 0.49
NOTUM Q6P988 1/20 0.48
HTR3E A5X5Y0 1/20 0.47
HTR3B O95264 1/20 0.47
HTR3A P46098 1/20 0.47
HTR3D Q70Z44 1/20 0.47
HTR3C Q8WXA8 1/20 0.47
KDR P35968 1/20 0.47
KIF11 P52732 1/20 0.47
KCNN4 O15554 1/20 0.44
TRPV1 Q8NER1 2/20 0.43
LMNA P02545 1/20 0.43
ABCB11 O95342 1/20 0.43
OPRL1 P41146 2/20 0.43
OPRM1 P35372 1/20 0.43
PDK1 Q15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29556319 1.00 IDO1 (0.61) IDO1S1PR1PYCR1GPR84NOTUM
SCHEMBL5513337 0.85 KIF11 (0.63) IDO1S1PR1PYCR1GPR84NOTUM
SCHEMBL5722021 0.85 TRPV1 (0.58) IDO1S1PR1PYCR1GPR84NOTUM
SCHEMBL2152251 0.84 KIF11 (0.51) IDO1S1PR1NOTUMKIF11TRPV1
SCHEMBL29844250 0.84 KIF11 (0.51) IDO1S1PR1NOTUMKIF11TRPV1
SCHEMBL10656615 0.83 IDO1 (0.65) IDO1PYCR1GPR84NOTUMHTR3E
SCHEMBL18235655 0.83 AR (0.52) IDO1S1PR1
SCHEMBL8443136 0.82 GPR84 (0.58) IDO1S1PR1PYCR1GPR84NOTUM
SCHEMBL932921 0.82 IDO1 (0.62) IDO1PYCR1GPR84NOTUMHTR3E
SCHEMBL29918384 0.81 IDO1 (0.50) IDO1S1PR1GPR84KDRKIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108997208-A A kind of preparation method of Sorafenib 山东罗欣药业集团恒欣药业有限公司 2018-12-14 CN claimed
EP-4192809-B1 PROCESS FOR THE PREPARATION OF A KEY INTERMEDIATE OF SIPONIMOD OLON SPA (IT) 2025-09-03 EP disclosed
US-20250074874-A1 SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2025-03-06 US disclosed
US-20230322658-A1 PROCESS FOR THE PREPARATION OF A KEY INTERMEDIATE OF SIPONIMOD OLON S.P.A. (IT) 2023-10-12 US disclosed
US-20230257349-A1 SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS ARENA PHARMACEUTICALS, INC. 2023-08-17 US disclosed
EP-3763367-A1 PYRIDINE-PYRAZOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS Celgene Quanticel Research, Inc. (US) 2021-01-13 EP disclosed
US-20200407316-A1 SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS ARENA PHARMACEUTICALS, INC. 2020-12-31 US disclosed
EP-2928471-B1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2020-10-14 EP disclosed
CN-104311472-B9 Substituted 1,2,3, 4-tetrahydrocyclopenta [ b ] indol-3-yl acetic acid derivatives 艾尼纳制药公司 2020-03-17 CN disclosed
CN-104311472-B Substituted 1,2,3, 4-tetrahydrocyclopenta [ b ] indol-3-yl acetic acid derivatives 艾尼纳制药公司 2019-12-31 CN disclosed
CN-1787817-A Immunosuppressant compounds and compositions IRM LLC (BM) 2006-06-14 CN disclosed
US-7060697-B2 Immunosuppressant compounds and compositions IRM LLC (BM) 2006-06-13 US disclosed
EP-1638551-A2 IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS IRM LLC (BM) 2006-03-29 EP disclosed
WO-2005082089-A2 IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS IRM LLC (BM) 2005-09-09 WO disclosed
US-20050014724-A1 Immunosuppressant compounds and compositions IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) 2005-01-20 US disclosed
WO-2004103309-A2 IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS IRM LLC (BM) 2004-12-02 WO disclosed
EP-0034415-B1 1-(CYCLOHEXYL OR CYCLOHEXENYL)-4-ARYL-4-PIPERIDINECARBOXYLIC ACID DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1984-05-30 EP disclosed
US-4369184-A ANTIHISTAMINES; HETEROCYCLIC NITRILES JANSSEN PHARMACEUTICA N.V. (BE) 1983-01-18 US disclosed
EP-0034415-A1 1-(Cyclohexyl or cyclohexenyl)-4-aryl-4-piperidinecarboxylic acid derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1981-08-26 EP disclosed
US-4063022-A GASTRIC ACID MORTON-NORWICH PRODUCTS, INC. (US) 1977-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200407316-A1 SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS S1PR1, S1PR3, S1PR2 IDO1 14/4885S1PR1 1/4885PYCR1 347/4885
US-20230257349-A1 SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS S1PR1, S1PR3, S1PR2 IDO1 14/4885S1PR1 1/4885PYCR1 347/4885
US-20230322658-A1 PROCESS FOR THE PREPARATION OF A KEY INTERMEDIATE OF SIPONIMOD S1PR5, S1PR2, S1PR4 IDO1 1086/4885S1PR1 5/4885PYCR1 2488/4885
US-20250074874-A1 SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS S1PR1, S1PR3, S1PR2 IDO1 14/4885S1PR1 1/4885PYCR1 347/4885
US-20050014724-A1 Immunosuppressant compounds and compositions ICOS, EDNRA, NFATC1 IDO1 28/4885S1PR1 133/4885PYCR1 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.